

LIST of the 363 references included in the systematic review

ARCHER 1009 2014

- Ramalingam SS. ARCHER 1009: A Study of Dacomitinib (PF-00299804) Vs. Erlotinib in The Treatment of Advanced Non-Small Cell Lung Cancer (ARCHER 1009). clinicaltrials.gov. April 2017: NCT01360554.
- Clinicaltrials.gov. Update May 2017: NCT01360554.
- Ramalingam SS, Janne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial. *The Lancet Oncology*. 2014;15(12):1369 - 78.
- Ramalingam SS, Janne PA, Mok T, O'Byrne K, Boyer MJ, Zhang H, et al. Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009). *Journal of Clinical Oncology*. 2014;32(15):8018.
- Mok T, O'Byrne K, Ramalingam S, Janne P, Boyer M, Ahn J, et al. Dacomitinib versus Erlotinib in second/third line NSCLC: outcome for asian patients from the ARCHER 1009 Global Phase 3 trial. *Annals of Oncology*. 2014;25(4): iv426–iv70.

ARQ 197-209 2011

- Sequist LV, Von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. *Journal of Clinical Oncology*. 2011;29(24):3307-15.
- Von Pawel J, Akerley W, Brugger W, Ferrari D, Garmey E, Gerbe D, et al. Final results from Arq 197- 209: A global randomized placebo controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naïve patients with advanced non-small cell lung cancer (NSCLC). *Journal of Thoracic Oncology*. 2010;5(12): S501.
- Schiller J, Akerley W, Brugger W, Ferrari D, Garmey E, Gerber D, et al. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2010;28(18): LBA7502.
- Sequist L, Akerley W, Brugger W, Ferrari D, Garmey E, Gerber D, et al. Final results from ARQ 197- 209: a global randomized placebo-controlled Phase II clinical trial of Erlotinib plus ARQ 197 versus Erlotinib plus Placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer. *Annals of Oncology*. 2010;21(8): viii122–viii61.

ATTENTION 2015

- Yoshioka H, Azuma K, Yamamoto N, Takahashi T, Nishio M, Katakami N, et al. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ-197) in Asian patients with previously treated stage IIIB/IV nonsquamous non-small-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). *Ann Oncol*. 2015;26(10):2066- 72.

Bergqvist 2014

- Bergqvist M, Holgersson G, Bondarenko I, Grechanaya E, Maximovich A, Andor G, et al. Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer. *Acta oncologica*. 2017;56(3):441-7.
- Bergqvist M, Bondarenko I, Thuresson M, Klockare M, Harmenberg J. Randomized, controlled, multicenter, multinational phase 2 study of docetaxel (DCT) or AXL1717 treatment in patients with squamous cell carcinoma (SCC) or adenocarcinoma (AC) of non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2014;32(5s): abstr 8091.
- Axelar website: "Randomized, Controlled, Multicenter, Multinational Phase II Study of Docetaxel (DCT) or AXL1717 Treatment in Patients with Squamous Cell Carcinoma (SCC) or Adenocarcinoma (AC) of Non-Small Cell Lung Cancer (NSCLC)". <http://www.axelar.se/rd/posters-publications/>

Besse 2014

- Besse B, Leighl N, Bennouna J, Papadimitrakopoulou VA, Blais N, Traynor AM, et al. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. *Annals of Oncology*. 2014;25(2):409 - 15.
- Bennouna J, Besse B, Leighl NB, Blais N, Traynor AM, Papadimitrakopoulou V, et al. Everolimus plus erlotinib versus erlotinib alone in previously treated patients with advanced non-small-cell lung cancer

(NSCLC). Annals of Oncology. 2010;21: viii140.

- Leighl NB, Soria J, Bennouna J, Blais N, Traynor AM, Papadimitrakopoulou V, et al. Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2010;28(15): 7524.

- Novartis report 2014: <https://www.clinicaltrials.gov/ct2/show/study?term=NCT00130728&rank=1>

BeTa 2011

- Herbst R. A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in combination with Tarceva (Erlotinib) compared with Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First- Line Chemotherapy. Clinicaltrials.gov. November 2009: NCT00130728.
- Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial. The Lancet. 2011;377(9780):1846 - 54.

Bhatnagar 2012

- Bhatnagar AR, Singh DP, Sharma R, Kumbhaj P. Docetaxel versus gefitinib in patients with locally advanced or metastatic NSCLC pretreated with platinum-based chemotherapy. Journal of Thoracic Oncology. 2012;7(9): S159.

Blumenschein 2015

- Blumenschein G. A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC Stage IV). Clinicaltrials.gov. June 2013: NCT01362296.
- Blumenschein G, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, et al. A randomized phase 2 study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 2015. pii: mdv072.
- Blumenschein GR, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, et al. MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2013;31(15) : 8029.
- GSK report 2015: <http://www.gsk-clinicalstudyregister.com/files/2/373c6bed-07dd-4af1-a2bb-80019d5c705f>

BR21 2005

- EMA 2005 Report: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000618/WC500033991.pdf
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-32.
- Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology. 2008;26(26):4268-75.
- NICE report 16/12/2015: <https://www.nice.org.uk/guidance/ta374>

CALGB 30704 2014

- Heist R. A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer. Clinicaltrials.gov. February 2015: NCT00698815.
- Clinicaltrials.gov. Update January 2018: NCT00698815
- Heist RS, Wang X, Hodgson L, Otterson GA, Stinchcombe TE, Gandhi L, et al. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. Journal of Thoracic Oncology. 2014;9(2): 214 - 21.
- Heist RS, Wang XF, Hodgson L, Otterson GA, Stinchcombe T, Vokes EE, et al. CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2012; 30(15).

CheckMate 017 2015

- FDA 11/2015 report: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125554s012lbl.pdf

- EPAR 14/01/2016 report: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003840/WC500190648.pdf
- Brahmer J. Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer (NSCLC) (CheckMate 017). Clinicaltrials.gov. February 2016; NCT01642004.
- Clinicaltrials.gov. Update April 2018; NCT01642004.
- Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N Engl J Med*. 2015; 373(2):123– 35.
- Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). *J Clin Oncol*. 2017 Dec 10;35(35):3924-33.
- Reck M, Taylor F, Penrod JR, DeRosa M, Morrissey L, Dastani H, et al. Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study. *Journal of Thoracic Oncology*. 2018;13(2):194-204.
- Borghaei H, Lynch TJ, Rizvi NA, Chow LQM, Reilly R, Crino L, et al. A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2013;31(15).
- Spigel DR, Reckamp KL, Rizvi NA, Poddubskaya E, West HJ, Eberhardt WEE, et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2015;33(15):8009.
- Reck M, Coon C, Taylor F, DeRosa M, Penrod J, Dastani H, et al. Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017. *European Journal of Cancer*. September 2015;51(Supplement 3): S599.
- Gralla RJ, Reck M, Taylor F, Orsini L, Penrod JR, Coon C, et al. Evaluation of disease-related symptoms in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel. *Journal of Thoracic Oncology*. 2015;10(9): S233-S4.
- Borghaei H, Brahmer JR, Horn L, Ready N, Steins M, Felip E, et al. Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. *Journal of Clinical Oncology*. 2016;34(Supplement): abstract 9025.
- Reckamp K, Brahmer JR, Spigel DR, Rizvi NA, Poddubskaya E, West H, et al. Phase 3, randomized trial (checkmate 017) of nivolumab (NIVO) vs docetaxel in advanced squamous (SQ) cell non-small cell lung cancer (NSCLC). *Journal of Thoracic Oncology* 2015;10(9): S174-S5.
- Venkatachalam M, Stenehjem DD, Pietri G, Penrod JR, Korytowsky B. Healthcare Resource Utilization in Patients with Advanced NSCLC in CheckMate 017 and 057 Based on Treatment-Related Adverse Events. *Annals of Oncology*. 2016;27(Supplement 6):1220P.
- Barlesi F, Steins M, Horn L, Ready N, Felip E, Borghaei H, et al. Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update. *Annals of Oncology*. 2016;27(Supplement 6): vi416–vi54.
- Reck M, Coon C, Taylor F, Derosa M, Penrod JR, Dastani H, et al. Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017. *Annals of Oncology*. 2015;26(Supplement 9): ix125-ix47 (abstract 460P).
- Felip Font E, Gettinger SN, Burgio MA, Antonia SJ et al. Three-Year Follow-up From CheckMate 017/057: Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer. *Annals of Oncology*. 2017;28 (Supplement 5) 1301PD.
- Nice report 1 November 2017: <https://www.nice.org.uk/guidance/ta484/resources/nivolumab-for-previously-treated-nonsquamous-nonsmallcell-lung-cancer-pdf-82605026489029>
- HAS report 2018: https://www.has-sante.fr/portail/upload/docs/evamed/CT-14655_OPDIVO_PIC_INS_Avis3_CT14655.pdf
- BMS 01/2016: http://packageinserts.bms.com/pi/pi_opdivo.pdf

CheckMate 057 2015

- FDA 11/2015 report: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125554s012lbl.pdf
- EMA report 2017: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf
- Borghaei H. Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic

- Non-squamous NSCLC (CheckMate057). Clinicaltrials.gov. January 2016: NCT01673867.
- Clinicaltrials.gov. Update April 2018: NCT01673867.
 - Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med*. 2015 Oct 22;373(17):1627-39.
 - Reck M, Brahmer J, Bennett B, Taylor F, Penrod JR, DeRosa M, et al. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. *Eur J Cancer*. 2018 Oct;102:23–30.
 - Gettinger SN, Brahmer JR, Rizvi NA, Ready N, Chow LQM, Antonia SJ, et al. A phase III comparative study of nivolumab (anti-PD-1; BMS-963558; ONO-4538) versus docetaxel in patients (pts) with previously treated advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2013;31(15).
 - Paz-Ares L, Horn L, Borghaei H, Spigel D, Steins M, Ready N, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non- SQ) non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2015;33(suppl; abstr LBA109).
 - Horn L, Brahmer J, Reck M, Borghaei H, Spigel D, Steins M, et al. Phase 3, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer(NSCLC): Subgroup analyses and patient reported outcomes (PROs). *European Journal of Cancer*. 2015;51(Supplement 3): S1-S810.
 - Li A, Fayette J, Reck M, Spigel D, Barlesi F, Ready N, et al. Phase 3, randomized trial (CheckMate 057) of nivolumab (NIVO) vs. Docetaxel (DOC) in advanced non-squamous (non- SQ) non-small cell lung cancer (NSCLC)-subgroup analyses and patient reported outcomes (PROs). *Oncology Research and Treatment*. 2016;39: 27.
 - Li A, Fayette J, Reck M, Vokes EE, Barlesi F, Felip E, et al. Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs). *Annals of Oncology*. 2015;26: ix125.
 - Gralla RJ, Spigel DR, Bennett B, Taylor F, Penrod JR, DeRosa M, et al. Lung Cancer Symptom Scale (LCSS) as a marker of treatment (tx) benefit with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC from CheckMate 057. *Journal of Clinical Oncology*. 2016;34(Supplement): abstract 9031.
 - Reck M, Brahmer J, Bennett B, Taylor F, Penrod JR, DeRosa M, et al. Overall Health Status in Patients With Advanced Non-Squamous NSCLC Treated With Nivolumab or Docetaxel in CheckMate 057. *Annals of Oncology*. 2016;27(Supplement 6): abstract 1217PD.
 - IQWiG report 2016 : https://www.iqwig.de/download/A16-25_Nivolumab_Extract-of-dossier-assessment_V1-0.pdf
 - BMS 01/2016: http://packageinserts.bms.com/pi/pi_opdivo.pdf

Chen 2011

- Chen Y-M, Fan W-C, Tsai C-M, Liu S-H, Shih J-F, Chou T-Y, et al. A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. *Lung Cancer*. 2011;6(6):1110-6.

CTONG0806 2014

- Zhou Q, Cheng Y, Yang JJ, Zhao MF, Zhang L, Zhang XC, et al. Pemetrexed versus gefitinib as a second- line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. *Annals of Oncology*. 2014;25(12):2385-91.
- Yang J, Cheng Y, Zhao M, Zhou Q, Yan HH, Zhang L, et al. A phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806). *Journal of Clinical Oncology*. 2013;31(15).

Dai 2013

- Dai H, Xu L, Xia C, Chen W. A randomized clinical study of gefitinib and pemetrexed as second line therapy for advanced non-squamous non-small cell lung cancer. *Chinese Journal of Lung Cancer*. 2013;16(8):405 - 10.

DATE 2015

- Kim HR, Jang JS, Sun JM, Ahn MJ, Kim DW, Jung I, et al. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). *Oncotarget*. 2016;28, 8(9):15943-51.
- Kim H, Jang J, Sun J, Ahn M, Kim D, Jung I, et al. A randomized, phase II study of nimotuzumab plus gefitinib vs gefitinib in advanced non-small cell lung cancer after platinum- based chemotherapy. *Journal of Thoracic*

Oncology. 2015;10(9): Supplement 2 (S663-S4).

DELTA 2014

- Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and erlotinib lung cancer trial (DELTA). *Journal of Clinical Oncology*. 2014;32(18):1902 - 8.
- Okano Y, Ando M, Asami K, Fukuda M, Nakagawa H, Ibata H, et al. Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA). *Journal of Clinical Oncology*. 2013;31(15): 8006.
- Ibata H, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, et al. Updated overall survival (OS) results of randomized phase III trial of erlotinib (E) versus (v) docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC): Docetaxel and Erlotinib Lung Cancer Trial (DELTA). *Journal of Clinical Oncology*. 2014;32(15): e19003.

Dittrich 2014

- Dittrich C. A Phase 2 Study of Pemetrexed Versus Pemetrexed Plus Erlotinib in Second-Line Treatment in Patients With Nonsquamous NSCLC. *Clinicaltrials.gov*. June 2011: NCT00447057.
- Dittrich C, Papai-Szekely Z, Vinolas N, Sederholm C, Hartmann JT, Behringer D, et al. A randomised phase II study of pemetrexed versus pemetrexed + erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer. *European journal of cancer*. 2014;50(9):1571-80.
- Von Pawel J, Papai-Szekely Z, Vinolas N, Sederholm C, Klima M, Desai D, et al. A randomized phase 2 study of pemetrexed vs. pemetrexed+erlotinib in second-line treatment for locally advanced or metastatic, non-squamous NSCLC. *Journal of Clinical Oncology*. 2011;29(15):7526.

E1512 2015

- Neal JW. Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients with Stage IV Non-Small Cell Lung Cancer. *Clinicaltrials.gov*. November 2016; NCT01708954.
- Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, et al. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. *Lancet Oncol*. 2016;17(12):1661-71.
- Neal J, Dahlberg S, Wakelee H, Aisner S, Bowden M, Carbone D, et al. Cabozantinib (C), erlotinib (E) or the combination (E+C) as second- or third-line therapy in patients with EGFR wild-type (wt) non- small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512). *Journal of Clinical Oncology*. 2015;33(15):8003.
- Neal J, Dahlberg S, Wakelee H, Aisner S, Bowden M, Carbone D, et al. A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512. *Journal of Thoracic Oncology*. 2015;10(9): Supplement 2.

Esteban 2003

- Esteban E, González de Sande L, Fernández Y, Corral N, Fra J, Muñoz I, et al. Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *Annals of Oncology*. 2003;14(11):1640- 7.
- Blay P, Esteban E, Fra J, Muniz I, Palacio I, Fernandez JL, et al. Randomized phase II study of weekly docetaxel (D) versus paclitaxel (P) in second line advanced non-small cell lung cancer (NSCLC): a Grupo Oncologico del Norte (GON) study. *Proceedings of the American Society of Clinical Oncology*. 2002;21 (Pt 2):214b, Abstract 2675.

Gerber 2014

- Gerber D, Socinski M, Neal J, Wakelee H, Shirai K, Sequist L, et al. Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) Metastatic Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*. 2014;90(5): Supplement 1.

GFPC 05-06 2011

- Vergnenegre A, Corre R, Berard H, Paillot D, Dujon C, Robinet G, et al. Cost-effectiveness of second- line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study. *Journal of Thoracic Oncology*. 2011 Jan; 6(1):161-8.

Groen 2013

- Groen H. Randomized, Double-Blind, Phase 2 Study of Erlotinib with or Without SU011248 In The Treatment Of Metastatic Non-Small Cell Lung Cancer. Clinicaltrials.gov. January 2011: NCT00265317.
- Groen HJM, Socinski MA, Grossi F, Juhasz E, Gridelli C, Baas P, et al. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). *Annals of Oncology*. 2013;24(9):2382 - 9.
- Groen HJM, Socinski M, Grossi F, Juhasz E, Gridelli C, Baas P, et al. Randomized phase II study of sunitinib (SU) plus erlotinib (E) vs. placebo (P) plus E for the treatment of metastatic non-small cell lung cancer (NSCLC). *Annals of Oncology*. 2010;21: viii139.

Hainsworth 2010

- Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. *Journal of Thoracic Oncology*. 2010; 5(10):1630 - 6.

Han 2011

- Han YH, Han QS, Liu SD. Comparison of pemetrexed and docetaxel as single chemotherapy in advanced non-small cell lung cancer. *Chinese Journal of Cancer Prevention and Treatment*. 2011;18(1):57 - 9.

HANSHIN Oncology Group 0110 2015

- Nishino K, Imamura F, Kumagaia T, Katakamib N, Hatab A, Okudab C, et al. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110). *Lung Cancer*. 2015; 89(2):146-53.

Herbst, 2007*

- Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. *Journal of Clinical Oncology*. 2007; 25(30):4743-50.

Heymach 2007

- Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. *Journal of Clinical Oncology*. 2007;25(27):4270 - 7.
- Herbst R, Johnson B, Rowbottom J, et al. ZD6474 plus docetaxel in patients with previously treated NSCLC: results of a randomized, placebo-controlled phase II trial. *Lung Cancer* 2005; 49 (suppl 2): S35.

HORG 2013

- Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study. *Cancer*. 2013;119(15):2754 - 64.
- Vamvakas L, Agelaki S, Kentepozidis NK, Karampeazis A, Pallis AG, Christophyllakis C, et al. Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. *Journal of Clinical Oncology*. 2010;28(15).

Hosomi 2015

- Hosomi Y. A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer. Clinicaltrials.gov. December 2015: NCT01703091.
- Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. *Lung cancer*. 2016;99: 186-93.
- Hosomi Y, Yoh K, Kasahara K, Yamada K, Takahashi T, Tanaka K, et al. Docetaxel + ramucirumab (DR) versus docetaxel + placebo (D) as second-line treatment for advanced non-small cell lung cancer(NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan. *Journal of Clinical Oncology*. 2015;33(15):8054.

ICOGEN 2013

- Shi Y. A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated with Chemotherapy. Clinicaltrials.gov. February 2012: NCT01040780.
- Shi Y, Zhang L, Liu X, Zhou C, Zhang S, Wang D, et al. Icotinib versus gefitinib in previously treated advanced

non-small-cell lung cancer (ICOGEN): A randomised, double-blind phase 3 non-inferiority trial. The Lancet Oncology. 2013;14(10):953 - 61.

- Shi Y. A Randomized, Double-Blind, Double Dummy, Multicenter Phase II/III Trial to Evaluate the Safety and Efficacy of Icotinib and Gefitinib in Advanced NSCLC Patients Previously Treated with Chemotherapy. May 2015: ChiCTR-TRC-09000506.
- Sun Y, Shi Y, Zhang L, Liu X, Zhou C, Wang D. A randomized, double blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (icogen). Journal of Thoracic Oncology. 2011;6(6): S317-S8.
- Sun Y, Shi Y, Zhang L, Liu X, Zhou C, Zhang L, et al. Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial. Journal of Clinical Oncology. 2012;30(15):7559.
- Yan S, Yuankai S, Li Z, Xiaoqing L, Zhou C, Li Z, et al. Final overall survival and updated biomarker analysis results from the randomized Phase III ICOGEN Trial. Annals of Oncology. 2012;23(9): ix416.

INTEREST 2008

- Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. The Lancet. 2008;372(9652):1809 - 18.
- Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. Journal of Clinical Oncology. 2010;28(5):744 - 52.

ISEL 2005

- Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). The Lancet. 2005. p. 1527-37.
- Chang A, Parikh P, Thongprasert S, Tan EH, Perng RP, Ganzon D, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study. Journal of Thoracic Oncology. 2006;1(8):847 - 55.

ISTANA 2010

- Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clinical Cancer Research. 2010;16(4):1307 - 14.

Janne 2013

- Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. The Lancet Oncology. 2013;14(1):38 - 47.
- Janne P, Shaw A, Pereira J, Jeannin G, Vansteenkiste J, Barrios C, et al. Efficacy and patient-reported outcomes with Selumetinib (AZD6244, ARRY-142866; SEL) + Docetaxel (DOC) in KRAS-mutant advanced non-small cell lung cancer: a randomized Phase II trial. Annals of Oncology. 2012;23(9):ix403- 1233PD.
- Janne P, Tsang Shaw A, Rodrigues Pereira J, Jeannin G, Vansteenkiste J, Barrios C, et al. Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2012;30(15):7503.

JMEI 2004

- EMA 2004 report: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Scientific_Discussion/human/000564/WC500025606.pdf
- Hanna N, Shepherd FA, Fossella FV, Pereira JR, Demarinis F, Von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Journal of Clinical Oncology. 2004;22(9):1589 - 97.
- NICE report 22/08/2007: <https://www.nice.org.uk/guidance/ta124>
- HAS report 2016: https://www.has-sante.fr/portail/upload/docs/application/pdf/2016-06/alimta_cbnpc_pic_reev_avis2modifie_ct14873.pdf
- Lilly report 12/11/2004: [CT Registry ID# 488; Clinical Study Summary: Study H3E-MC-JMEI](http://lillytrials.com/results/alimta.pdf)

Jones 2008

- Jones S, Thompson D, Barton J, Patton J, Shipley D, Greco FA, et al. A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer. Clinical lung cancer. 2008;9(3):154-9.

Juan 2014

- Juan Ó, Aparisi F, Sánchez-Hernández A, Muñoz-Langa J, Esquerdo G, García-Sánchez J, et al. Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial. *Clinical Lung Cancer*. 2014 Nov 23. pii: S1525-7304.
- Aparisi F, Garcia Sanchez J, Sanchez-Hernandez A, Giner V, Munoz-Langa J, Esquerdo G, et al. Multicenter, open, randomized, phase II study to investigate the sequential administration of docetaxel and intermittent erlotinib versus erlotinib as a second-line therapy for advanced non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2011;29(15).
- Aparisi F, Sanchez A, Giner V, Munoz J, Esquerdo G, Garde J, et al. A Multi-center, Open, Randomized, Phase II Study to Investigate the Sequential Administration of Docetaxel and Intermittent Erlotinib Versus Erlotinib as a Second-line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC). *European Journal of Cancer*. 2011;47(S1): S630.
- Vidal O, Sánchez J, Sánchez A, Giner V, Munoz Langa J, Esquerdo G, et al. Clinical benefits of sequential administration of docetaxel and intermittent erlotinib as a second-line therapy for advanced non-small cell lung cancer (NSCLC), a phase II randomized study. *Journal of Thoracic Oncology*. 2011;6(6): P3.030.

Kapoor 2015

- Kapoor A, Kumar N, Narayan S, Nirban R, Maharia S, Beniwal S, et al. A prospective randomized open label phase III study of gefitinib versus docetaxel as second or third line therapy in patients with advanced non-small cell lung cancer in Asian indians. *Annals of Oncology*. 2015;26(Supplement 1): i29–i44.

Katakami 2014

- Katakami N, Yoshioka H, Okamoto H, Iwamoto Y, Seto T, Takahashi T, et al. Amrubicin (AMR) versus Docetaxel (DTX) as second- or third-line treatment for non-small cell lung cancer (NSCLC): a randomized phase III trial. *Annals of oncology*. 2014;25((Supplement 4)): iv 426-iv70.

KCSG-LU08-01 2012

- Sun JM, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, et al. Gefitinib versus pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): An open-label, phase 3 trial. *Cancer*. 2012;118(24):6234 - 42.
- Ahn M, Sun J, Ahn JS, Kim S, Lee KH, Min YJ, et al. Randomized phase III trial of gefitinib or pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum- based chemotherapy (KCSG-LU08-01). *Journal of Clinical Oncology*. 2011;29(15).
- Ahn M, Sun J, Lee K, Ahn J, Kim S, Min Y, et al. Randomized Phase III trial of Gefitinib or Pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum- based chemotherapy (KCSG-LU08-01). *Journal of Thoracic Oncology*. 2011;6(6): S317.

Kelly 2012

- Kelly K. A Randomized, Phase 2b, Multi-center Study of Pralatrexate Versus Erlotinib in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based Treatment. *Clinicaltrials.gov*. December 2010: NCT00606502.
- Kelly K, Azzoli CG, Zatloukal P, Albert I, Jiang PY, Bodkin D, et al. Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy. *Journal of Thoracic Oncology*. 2012 Jun;7(6):1041-8.
- Kelly K, Azzoli CG, Patel JD, Weems G, Zatloukal P. Randomized phase 2B study of pralatrexate vs erlotinib in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) after failure of prior platinum- based therapy. *Annals of Oncology*. 2010;21: viii8.

KEYNOTE-010 2016

- FDA report 2017: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s017s018lbl.pdf
- EMA report 2017: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003820/WC500190990.pdf
- Herbst RS. Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010). *Clinicaltrials.gov*. May 2017: NCT01905657.
- Clinicaltrials.gov. Update February 2018: NCT01905657.
- Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*. 2016; 387(10027):1540-50.
- NICE report 2017: <https://www.nice.org.uk/guidance/ta428/resources/pembrolizumab-for-treating->

pdl1positive-nonsmallcell-lung-cancer-after-chemotherapy-pdf-82604670410437

- IQWiG report 2016: https://www.iqwig.de/download/A16-55_Pembrolizumab_Extract-of-dossier-assessment-V1-0.pdf.
- Herbst R, Gorpide A, Surmont V, Kim D, Waqar S, Herder J, et al. A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer. *Journal of Clinical Oncology*. 2014;32(15 Supplement): TPS8124.
- Baas P, Garon EB, Herbst RS, Felip E, Perez-Gracia JL, Han J-Y, et al. Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1-Positive NSCLC. *Journal of Clinical Oncology*. 2016;34 (Supplement): abstract 9015.
- Garon EB, Herbst RS, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010. *Journal of Clinical Oncology*. 2016;34(Supplement): abstract 9024.
- Herbst R, Garon E, Kim DW, Cho BC, Gadgeel S, Léna H, et al. Keynote-010: Durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed pembrolizumab. *Journal of Thoracic Oncology*. 2017;12(1): S254-S5.
- Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Expressing NSCLC: Updated Outcomes of KEYNOTE-010. *Annals of Oncology*. 2016;27(Supplement 6):vi416-54.
- Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, et al. Assessment of Health-Related Quality of Life in KEYNOTE-010: A Phase 2/3 Study of Pembrolizumab Versus Docetaxel in Patients with Previously Treated Advanced NSCLC. *Annals of Oncology*. 2016;27(Supplement 6):vi416-vi54.
- Herbst RS, Garon EB, Kim D-W, Chul Cho B, Pérez Gracia JL, Han J-Y, et al. LBA63Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). *Annals of Oncology [Internet]*. 2018 Oct 1 [cited 2019 Feb 20];29(suppl_8). Available from: <https://academic.oup.com/annonc/article/doi/10.1093/annonc/mdy424.075/5142142>

Kim A 2012

- Kim E. Randomized Phase III Study of Docetaxel or Pemetrexed with or Without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy. *Clinicaltrials.gov*. June 2012: NCT00095199.
- Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: A phase 3, open-label, randomised trial. *The Lancet Oncology*. 2013;14(13):1326 - 36.

Kim B 2012

- Kim E. Randomized Phase III Study of Docetaxel or Pemetrexed with or Without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy. *Clinicaltrials.gov*. June 2012: NCT00095199.

Kim 2015

- Kim Y, Cho E, Woo H, Hong J, Ahn H, Park I, et al. Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. *Cancer Res Treat* 2015. doi: 10.4143/crt.2014.307.
- Kim YS, Cho EK, Sym SJ, Hong J, Park I, Ahn HK, et al. Randomized phase II study of pemetrexed versus gefitinib in previously treated patients with advanced non-small cell lung cancer. *Journal of Clinical Oncology*. 2014;32(15): e19039.
- Hong J, Kyung SY, Lee SP, Park JW, Jung SH, Sym SJ, et al. Randomized phase II study of pemetrexed versus gefitinib for patients with previously treated non-small cell lung cancer. *Journal of Thoracic Oncology*. 2010;5(12): S401.
- Cho E, Kyung S, Sym S, Kim Y, Lee S, Park J, et al. Randomized phase II trial of pemetrexed versus gefitinib in previously treated non-small cell lung cancer: preliminary results. *Journal of Thoracic Oncology*. 2009;4(9): S672.

Krzakowski 2010

- Krzakowski M, Ramlau R, Jassem J, Szczesna A, Zatloukal P, Von Pawel J, et al. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. *Journal of Clinical Oncology*. 2010;28(13):2167-73.

Kuo 2013

- Kuo H. Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). *Clinicaltrials.gov*. August 2013: NCT00536107.

- Pharmaceutical report: <http://www.astrazenecaclinicaltrials.com/Submission/View?id=2086>

Lee 2013

- Lee DH. A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed Alone, and Erlotinib Alone, as Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. Clinicaltrials.gov. January 2013: NCT00550173.
- Lee DH, Lee JS, Kim SW, Rodrigues-Pereira J, Han B, Song XQ, et al. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. Eur J Cancer. 2013;49(15):3111-21.
- Lee D, Lee J, Kim S, Rodrigues Pereira J, Han B, Song X, et al. A randomized Phase 2 study of Erlotinib plus Pemetrexed versus Erlotinib or Pemetrexed alone as second-line treatment for never-smoker patients with non-squamous advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 2012;23(9): ix400–ix46.
- Lee D, Lee J, Wang J, Hsia T, Wang X, Kim J, et al. Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial. Cancer Research and Treatment 2015; 47(4):616-29.

Levy 2014

- Levy B, Spira A, Becker D, Evans T, Schnadig I, Camidge DR, et al. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. Journal of Thoracic Oncology. 2014;9(7):1031 - 5.

Li 2010

- Li H, Wang X, Hua F. Second-line treatment with gefitinib or docetaxel for advanced non-small cell lung cancer. Chinese Journal of Clinical Oncology. 2010;37(1):16 - 8.

Li 2012

- Li R, Sun L, Wang J, Qian J, Wang Z, Jiao X. Pemetrexed versus docetaxel in second line non-small-cell lung cancer: Results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients. Pulmonary Pharmacology and Therapeutics. 2012;25(5):364 - 70.

Li 2013

- Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, et al. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clinical lung cancer. 2017;18(1):60-7.
- Li T, Piperdi B, Walsh W, Kim M, Gucalp R, Haigentz M, et al. Randomized phase II study of pharmacodynamic separation (PDS) of pemetrexed (Pem) and erlotinib (Erl) versus pem alone in patients (pts) with advanced non-small cell lung cancer (NSCLC). Journal of Clinical oncology. 2013;31(5):8097.
- Li T, Piperdi B, Walsh W, Kim M, Beckett L, Wen H, et al. Pharmacodynamic separation (PDS) of pemetrexed (Pem) and erlotinib (Erl) in patients (pts) with advanced, EGFR wild-type (wt) Non-Small Cell Lung Cancer (NSCLC): A randomized phase II trial. Journal of Clinical Oncology 2015;33(15):8044.

Li 2014

- Wang S. A Randomized Phase II Trial of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced EGFR Wild-Type and EGFR FISH-Positive Lung Adenocarcinoma. Clinicaltrials.gov. September 2014: NCT01565538.
- Li N, Ou W, Yang H, Liu QW, Zhang SL, Wang BX, et al. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma. Cancer. 2014;120(9):1379 - 86.
- Wang SY, Li N, Ou W, Zhang L, Zhang SL. A phase II trial of erlotinib versus pemetrexed as second-line therapy in treating patients with advanced EGFR wild-type and EGFR fish-positive lung adenocarcinoma. Journal of Thoracic Oncology. 2013;8: S575.

Liu, 2015

- Liu Z, Wei Z, Hu Y, Gao F, Hao L, Fang P, et al. A phase II open-label clinical study of comparing nab- paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer. Med Oncol. 2015; 32(8):216.

LUME-COLUMBUS, 2017

- Boehringer I. LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-Small Cell Lung Cancer with Translational Research. Clinicaltrials.gov. February 2017: NCT02231164.
- Boehringer Ingelheim report 2017: https://trials.boehringer-ingenheim.com/public/trial_results_documents/1199/1199.128_Statement_DR.pdf

LUME-Lung 1 2014

- EMA 2015 report: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002569/WC500179970.pdf
- EMA update 2018: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002569/WC500179972.pdf
- Reck M. Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in Patients with Stage IIIB/IV or Recurrent Non-Small Cell Lung Cancer After Failure of First Line Chemotherapy. Clinicaltrials.gov. November 2014: NCT00805194.
- Clinicaltrials.gov. Update December 2017: NCT00805194.
- Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME- Lung 1): A phase 3, double-blind, randomised controlled trial. The Lancet Oncology. 2014;15(2):143 - 55.
- Novello S, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Analysis of patient- reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Eur J Cancer. 2015 Feb;51(3):317-26.
- NICE report 22/07/2015: <https://www.nice.org.uk/guidance/ta347>
- IQWiG report 30/03/2015: https://www.iqwig.de/download/A15-01_Nintedanib_Extract-of-dossier-assessment.pdf
- HAS report 2015: https://www.has-sante.fr/portail/upload/docs/evamed/CT-14048_VARGATEF_PIC_INS_Avis3_CT14048.pdf
- Reck M, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, Von Pawel J, et al. Nintedanib (BIBF 1120) + docetaxel as second-line therapy in patients with stage IIIB/IV or recurrent NSCLC: Results of the phase III, randomised, double-blind LUME-Lung 1 trial. Lung Cancer. 2014;83: S12.
- Reck M, Novello S, Mellemgaard A, Orlov S, Kaiser R, Barrueco J, et al. Impact of tumor burden on the overall survival analysis of the lume-lung 1 study: A randomized, double-blind phase 3 trial of nintedanib (BIBF 1120) + docetaxel in NSCLC patients progressing after first-line chemotherapy. Journal of Thoracic Oncology. 2013;8: S196.
- Mellemgaard A, Douillard JY, Novello S, Kaiser R, Orlov S, Krzakowski M, et al. Patient-reported outcomes from the lume-lung 1 trial: A randomised, double-blind, placebo-controlled phase III study in second-line advanced NSCLC patients. Journal of Thoracic Oncology. 2014;9(9): S152 - S3.
- Reck M, Kaiser R, Mellemgaard A, Douillard J, Orlov S, Krzakowski M, et al. Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. Journal of Clinical Oncology. 2013;31(18): LBA8011.
- Mellemgaard A, Kaiser R, Douillard JY, Orlov SV, Krzakowski MJ, Von Pawel J, et al. Analysis of overall survival in adenocarcinoma NSCLC patients receiving 2nd line combination treatment with nintedanib (BIBF 1120) + docetaxel in the LUME-Lung 1 trial: A randomized, double-blind, placebo-controlled phase 3 study. European Journal of Cancer. 2013;49: S798.
- Reck M, Buchner H, Gottfried M, Novello S, Mellemgaard A, Heigener D, et al. Tumour growth over time in patients with advanced non-small cell lung cancer treated with nintedanib plus docetaxel or placebo plus docetaxel: Analysis of data from the LUME-Lung 1 study. European Journal of Cancer. 2015;51: Supplement 3 (3102).
- Wu Y, Cheng Y, Kim B, Lu S, Gaschler-Markefski B, Kaiser R, et al. Efficacy of nintedanib/docetaxel in East Asian patients with lung adenocarcinoma (ADE): analysis from the LUME-Lung 1 study. Annals of Oncology. 2015;26: Supplement 9 (ix 133).
- Bondarenko I, Reck M, Krzakowski M, Bennouna J, Kaiser R, Novello S, et al. Efficacy of nintedanib/docetaxel after bevacizumab, pemetrexed or taxanes therapy. Journal of Thoracic Oncology. 2015;10(9):S323-S4.
- Heigener D, Gottfried M, Bennouna J, Bondarenko I, Douillard JY, Krzakowski M, et al. Efficacy and safety of nintedanib/docetaxel in patients with lung adenocarcinoma: further analyses from the LUME-Lung 1 study. Annals of Oncology. 2016;27(Supplement 6):abstract 1276P.
- Boehringer Ingelheim report 2016: https://trials.boehringer-ingelheim.com/public/trial_results_documents/1199/1199.14_119914c296153FU.pdf

LUME-LUNG 2 2013

- Hanna N. A Randomized Double-blind Multicenter Phase III Trial of Nintedanib Plus Pemetrexed vs.

Pemetrexed/ Placebo in Advanced or Recurrent Non-Small Cell Lung Cancer Patients After Failure of First Line Therapy. Clinicaltrials.gov. November 2014: NCT00806819.

- Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung cancer. 2016;102:65-73.
- Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, et al. Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. Journal of Clinical Oncology. 2013;31(15).
- Pharmaceutical Report: http://trials.boehringer-ingenheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1199/1199.14_U12-2160-01-PE-DS-DR.pdf?bcsi_scan_628cd39dca2568d2=0&bcsi_scan_filename=1199.14_U12-2160-01-PE-DS-DR.pdf

Lux-Lung 8 2015

- FDA report 2016: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201292s009lbl.pdf
- EMA report 2018: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002280/WC500206977.pdf
- Soria J. LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy. Clinicaltrials.gov October 2014: NCT01523587.
- Clinicaltrials.gov Update January 2018: NCT01523587.
- Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015 Aug;16(8):897-907.
- Felip E, Hirsh V, Popat S, Cobo M, Fülöp A, Dayen C, et al. Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clin Lung Cancer. 2018;19(1):74-83.
- Lu S, Li W, Zhou C, Hu C-P, Qin S, Cheng G, et al. Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung. Onco Targets Ther. 2018;11:8565-73
- NICE report 2017: <https://www.nice.org.uk/guidance/ta444/resources/afatinib-for-treating-advanced-squamous-nonsmallcell-lung-cancer-after-platinumbased-chemotherapy-terminated-appraisal-pdf-82604784624325>
- IQWiG report 2016: https://www.iqwig.de/download/A16-22_Afatinib_Extract-of-dossier-assessment.pdf
- Goss G, Lu S, Felip E, Ardizzoni A, Georgoulas V, Gadgeel S, et al. LUX-lung 8: A randomized, open-label, phase III trial of afatinib vs. erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy. Annals of Oncology 2012;23(SUPPL. 9): ix174.
- Soria J, Felip E, Cobo M, Lu S, Syrigos K, Lee K, et al. Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8). Journal of Clinical Oncology. 2015;33(15):8002.
- Gadgeel S, Dols M, Felip E, Soria J, Lee K, Lu S, et al. Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial. Journal of Clinical Oncology. 2015;33(15):8100.
- Hirsh V, Gadgeel S, Soria J, Felip E, Cobo M, Lu S, et al. LUX-lung 8: A global phase III trial of Afatinib (A) vs Erlotinib (E) as second-line treatment in Patients (Pts) with advanced Squamous Cell Carcinoma (SCC) of the lung following first-line platinum-based chemotherapy. Chest 2015;148(4): (meeting abstract).
- Lu S, Wang B, Goss GD, Felip E, Georgoulas V, Soria J-C, et al. Afatinib (A) vs erlotinib (E) as second-line treatment of patients (PTS) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Lux-lung 8 (LL8), a phase III global trial. Annals of Oncology. 2015;26: i34- i.
- Goss G, Felip E, Cobo M, Lu S, Syrigos K, Li K, et al. Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes. European Journal of Cancer. 2015;51: Supplement 3 (3084).

- Popat S, Felip E, Cobo M, Fulop A, Dayen C, Trigo J, et al. Second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung: patient-reported outcome (PRO) data from the global LUX-Lung 8 (LL8) Phase III trial. *European Journal of Cancer*. 2015;51: Supplement 3 (3085).
- Felip E, Soria JC, Cobo M, Lu S, Syrigos K, Lee KH, et al. Second-Line Afatinib versus Erlotinib for Patients with squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumour and Serum Biomarkers. *Journal of Thoracic Oncology*. 2017;12(1):P3.02b-003.
- Goss G, Cobo M, Lu S, Syrigos K, Morabito A, Albert I, et al. Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial. *Journal of Thoracic Oncology*. 2017;12(1): OA23.03.
- Goss GD, Lee KH, Felip E, Cobo M, Syrigos KN, Göker E, et al. Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, phase 3 LUX-Lung 8 (LL8) trial of afatinib (A) versus erlotinib (E) for the second-line treatment of advanced squamous cell carcinoma (SCC) of the lung. *Journal of Clinical Oncology*. 2016;34(e20510).
- Goss G, Lee KH, Felip E, Cobo M, Syrigos K, Goker E, et al. Evaluation of VeriStrat®, a serum proteomic test, in the randomised, open-label, Phase III LUX-Lung 8 trial of afatinib versus erlotinib for the second-line treatment of advanced squamous cell carcinoma of the lung. *Annals of Oncology*. 2016;27(Supplement 6): vi416-vi54.
- Goss GD, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, et al. 1442P Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial. *Annals of Oncology [Internet]*. 2018 Oct 1 [cited 2019 Feb 20];29(suppl_8). Available from: <https://academic.oup.com/annonc/article/doi/10.1093/annonc/mdy292.064/5142158>
- Boehringer-ingenheim report 2014: http://trials.boehringer-ingenheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1200/1200.125_c02191506-02_PE_DR.pdf

Maitland 2014

- Maitland M. A Randomized Phase II Trial Comparing Cetuximab with Concurrent Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer Refractory to Primary Treatment. *Clinicaltrials.gov*. December 2013: NCT00203931.
- Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, et al. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. *BMC Cancer*. 2014;14: 5.

Marangolo 2000

- Marangolo, Cognetti, Di C, Selvaggi, Scagliotti, G V. Preliminary results of a phase II randomized trial of docetaxel vs vinorelbine as second-line treatment in previously cisplatin-treated advanced non- small cell lung cancer (NSCLC). *Lung cancer (Amsterdam, Netherlands)* 2000;29(9 Suppl 1): S 75

MARQUEE 2013

- Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, et al. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients with Locally Advanced or Metastatic Nonsquamous Non- Small-Cell Lung Cancer. *Journal of Clinical Oncology*. 2015; 33(24):2667–74.
- Novello S, Scagliotti G, Ramlau R, Favaretto A, Barlesi F, Akerley W, et al. Efficacy analysis for molecular subgroups in marquee: A randomized, doubleblind, placebo-controlled, phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC). *Journal of Thoracic Oncology*. 2013;8: S901-S902.
- Scagliotti G, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, et al. MARQUEE: A randomized, double-blind, placebo-controlled, phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non- small-cell lung cancer (NSCLC). *European Journal of Cancer*. 2013;49: S798 - S9.
- Scagliotti G, Akerley W, Von Pawel J, Roder J, Shuster D, Schwartz B, et al. Retrospective evaluation, of the randomized Phase 3 MARQUEE trial of tivantinib (T) + erlotinib (E) versus placebo (P) + erlotinib (E) using VeriStrat in patients with previously treated nonsquamous NSCLC. *Cancer Research* 2015;75(15): supplement 1.

MARVEL 2013

- Adjei A. Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients

with Advanced Non-Small Cell Lung Cancer. Clinicaltrials.gov. November 2013: NCT00738881.

METLung 2014

- Spigel D, Edelman M, O'Byrne K, Paz-Ares L, Shames D, Yu W, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. *Journal of Clinical Oncology*. 2014;32(15):8000.

Moran 2014

- Moran T. A Study Evaluating Dalotuzumab (MK-0646) in Combination with Erlotinib for Participants with Non-Small Cell Lung Cancer (MK-0646-007). Clinicaltrials.gov. March 2017: NCT00654420.
- Moran T, Felip E, Keedy V, Borghaei H, Shepherd FA, Insa A, et al. Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. *Exp Hematol Oncol*. 2014;3(1):26.
- Rosell R, Moran T, Felip E, Torres JMS, Borghaei H, Guan S, et al. An open label, randomized ph II study evaluating dalotuzumab combined with erlotinib in patients with non-small cell lung cancer following failure of prior chemotherapy. *Journal of Thoracic Oncology*. 2011;6(6): S358 - S9.

Natale 2009

- Natale RB, Bodkin D, Govindan R, Sleekman BG, Rizvi NA, Cap. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study. *Journal of Clinical Oncology*. 2009;27(15):2523-9.
- Natale R, Bodkin D, Govindan R, et al. A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa™) in patients with NSCLC: results of a randomized, double-blind phase II study. *Lung Cancer* 2005; 49(suppl 2): S37.

NCCTG N0626 2011

- Adjei AA. Pemetrexed Disodium with or Without Sorafenib as Second-Line Therapy in Treating Patients with Stage IIIB or Stage IV Non-Small Cell Lung Cancer. Clinicaltrials.gov. February 2017: NCT00454194.
- Molina JR, Dy GK, Foster NR, Allen Ziegler KL, Adjei A, Rowland KM, et al. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. *Journal of Clinical Oncology*. 2011;29(15).

NCIC CTG BR.26 2014

- Ellis P. A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease. Clinicaltrials.gov. September 2014: NCT01000025.
- Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, et al. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): A double-blind, randomised, phase 3 trial. *The Lancet Oncology*. 2014;15(12):1379 - 88.
- Ellis PM, Liu G, Millward M, Perrone F, Shepherd FA, Sun S, et al. NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. *Journal of Clinical Oncology*. 2014;32(15).

NVALT-10, 2013*

- Aerts JG, Codrington H, Lankheet NA, Burgers S, Biesma B, Dingemans AM, et al. A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non- small-cell lung cancer patients: the NVALT-10 study. *Ann Oncol*. 2013 Nov; 24(11):2860-5.

OAK, 2016

- FDA report 2016: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761041lbl.pdf
- EMA report 20 July 2017: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004143/WC500235780.pdf
- Rittmeyer A. A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK). Clinicaltrials.gov January 2018: NCT02008227.
- Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet*. 2017;389(10066):255-65.
- Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, et al. Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer. *Journal of Thoracic Oncology*.

2018; 13(8): 1156-70.

- Bordonni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, et al. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer. *Clin Lung Cancer*. 2018;19(5):441-449.e4.
- Von Pawel J, Bordonni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, et al. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. *European Journal of Cancer*. 2019 Jan;107:124–32.
- Gadgeel S, Ciardiello F, Rittmeyer A, Barlesi F, Cortinovis D, Barrios C, et al. OAK, a randomized phase III study of atezolizumab vs docetaxel in patients with advanced NSCLC: Results from subgroup analyses. *Journal of Thoracic Oncology*. 2017;12(1):S9-S10.
- Hida T, Kaji R, Satouchi M, Ikeda N, Horiike A, Nokihara H, et al. Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study. *Clinical Lung Cancer*. 2018, 19(4) : e405-e415.
- Von Pawel J, Syrigos K, Mazieres J, Cortinovis D, Dziadziuszko R, Gandara DR et al. Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK. *Annals of Oncology*. 2017;28 (Supplement 5) 1314P.
- Gadgeel S, Kowanetz M, Zou W, Hirsch FR, Kerr KM, Gandara DR, et al. Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L1 NSCLC: Results from the randomized OAK study. *Annals of Oncology*. 2017;28 (Supplement 5) v460–v496. 1296O.
- Cortinovis D, Von Pawel J, Syrigos K, Maziere J, R. Dziadziuszko R et al. Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Phase III study OAK. *Annals of Oncology*. 2017;28 (Supplement 5) 1313P.
- Marinis F, Barles F, Rittmeyer A, Von Pawel J, Han J-Y, Kozloff M. et al. Survival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study. *Annals of Oncology*. 2017;28 (Supplement 5) 1310P.
- Bordonni R, Ciardiello F, Von Pawel J, D. Cortinovis D, P. He P, T. Karagiannis T et al. Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (NSCLC) (ID 9903).
- Gandara DR, Joachim Von Pawel JV, Richard N. Sullivan RN, Aslaug Helland A, Ji-Youn Han JY, Santiago Ponce Aix S, et al. Atezolizumab Treatment Beyond Disease Progression in Advanced NSCLC: results from the randomized phase III OAK study. *ASCO 2017*. <https://meetinglibrary.asco.org/record/145466/abstract>
- Nice report 16 May 2018: <https://www.nice.org.uk/guidance/ta520>
- IQWiG report 2018: Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V (German version)

Paz-Ares 2008

- Paz-Ares L, Ross H, O'Brien M, Riviere A, Gatzemeier U, Pawel J, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. *British Journal of Cancer*. 2008. p. 1608-13.

POPLAR, 2016

- Fehrenbacher L. A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR". *Clinicaltrials.gov*. April 2017: NCT01903993.
- Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. *Lancet*. 2016; 387(10030):1837-46.
- Spira A, Park K, Mazieres J, Vansteenkiste J, Rittmeyer A, Ballinger M, et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). *Journal of Clinical Oncology* 2015;33(15).
- Smith DA, Vansteenkiste JF, Fehrenbacher L, Park K, Mazieres J, Rittmeyer A, et al. Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR). *Journal of Clinical Oncology*. 2016;34(Supplement): abstract 9028.
- Mazieres J, Fehrenbacher L, Rittmeyer A, Spira AI, Park K, Smith DA, et al. Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: results from the randomized phase II study POPLAR. *Journal of Clinical Oncology*. 2016;34(Supplement): abstract 9032.

PROSE, 2013*

- Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. *Lancet Oncol* 2014;15(7):713-21.
- Sorlini C, Barni S, Petrelli F, Novello S, De Marinis F, De Pas TM, et al. PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology* 2011;29(15).
- Lazzari C, Novello S, Barni S, Aieta M, De Marinis F, De Pas T, et al. Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE). *Journal of Clinical Oncology* 2013;31(18).
- Gregorc V. Tissue biomarker analysis in PROSE, a randomized proteomic stratified phase III study of second line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (NSCLC). *European Journal of Cancer* 2013;49(2).

Ramalingam 2011

- Ramalingam SS, Spigel DR, Chen D, Steins MB, Engelman JA, Schneider CP, et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. *Journal of Clinical Oncology*. 2011;29(34):4574-80.
- Ramalingam S, Spigel D, Steins M, Engelman J, Schneider C, Novello S, et al. Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2011;29(15):7527.

Ramalingam 2012

- Ramalingam S. A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen. *Clinicaltrials.gov*. July 2015: NCT00769067.
- Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. *Journal of Clinical Oncology*. 2012;30(27):3337-44.
- Boyer MJ, Blackhall FH, Park K, Barrios CH, Krzakowski MJ, Taylor I, et al. Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT). *Journal of Clinical Oncology*. 2010;28(18).
- Ramalingam S, Boyer M, Park K, Barrios C, Krzakowski M, Taylor I, et al. Randomized Phase 2 study of PF299804, an irreversible human epidermal growth factor receptor (EGFR) inhibitor, versus Erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after chemotherapy failure: quantitative and qualitative benefits. *Annals of Oncology*. 2010;21(18): viii122–viii61.
- Boyer M, Blackhall F, Barrios C, Frank R, Heo D, Park K, et al. Overall Survival (OS) Results of a Randomized Phase 2 Trial of PF299804 versus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Chemotherapy. *Journal of Thoracic Oncology*. 2011;6(6): O10.07.

Ramlau 2006

- Ramlau R, Gervais R, Krzakowski M, Von Pawel J, Kaukel E, Abratt RP, et al. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. *Journal of Clinical Oncology*. 2006;24(18):2800 - 7.
- GSK report 09/07/2009 : <http://www.gsk-clinicalstudyregister.com/files2/20023.pdf>

Ramlau 2012

- Ramlau R. A Multinational, Randomized, Double-Blind Study Comparing Afibercept Versus Placebo in Patients Treated with Second-Line Docetaxel After Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. *Clinicaltrials.gov*. August 2012: NCT 00532155.
- Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, et al. Afibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: A randomized, controlled phase III trial. *Journal of Clinical Oncology*. 2012;30(29):3640 - 7.

REVEL 2014

- FDA report 04/2015: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125477s011lbl.pdf
- EMA report 2018: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002829/WC500203169.pdf
- Garon E. A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel

- and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy. Clinicaltrials.gov. December 2014: NCT01168973.
- Clinicaltrials.gov. Update August 2017: NCT01168973.
 - Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. *The Lancet*. 2014;384(9944):665 - 73.
 - Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB, et al. Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. *Cancer Chemotherapy and Pharmacology*. 2018; 82:77-86.
 - NICE report 2016 : <https://www.nice.org.uk/guidance/ta403/resources/ramucirumab-for-previously-treated-locally-advanced-or-metastatic-nonsmallcell-lung-cancer-pdf-82604541080005>
 - Reck M, Paz-Ares LG, Bidoli P, Cappuzzo F, Dakhil SR, Moro-Sibilot D, et al. Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2016;34(Supplement): abstract 9079.
 - Schuette W, Reck M, Kimmich M, Schumann C, Paz-Ares L, Garon E, et al. Exploratory analysis of efficacy by histology and frontline therapies in a nonsquamous non-small cell lung cancer (NSCLC) subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC plus placebo (PBO) for second-line treatment of stage IV NSCLC. *Oncology Research and Treatment*. 2016;39:90.
 - Kang JH, Park K, Kim J-H, Cho EK, Shih JY, Zimmermann AH, et al. Subgroup analysis of east asian patients in the phase III revel trial. *Journal of Thoracic Oncology*. 2015;10(9):S323.
 - Perol M, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy. *Journal of Clinical Oncology*. 2014;32(15).
 - Garon E, Ciuleanu T, Arrieta O, Prabhash K, Syrigos K, Göksel T, et al. Quality of life results from the Phase 3 REVEL study of Ramucirumab + Docetaxel versus Placebo + Docetaxel in advanced/metastatic NSCLC patients with progression after platinum based chemotherapy. *Annals of Oncology*. 2014;25(4): iv426–iv70.
 - Paz-Ares L, Perol M, Ciuleanu T, Kowalyszyn R, Reck M, Lewanski C, et al. Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2015; 33(15):8055.
 - Reck M, Smit E, Garon E, Cappuzzo F, Bidoli P, Cohen R, et al. Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase 3 REVEL trial (docetaxel [DOC] plus placebo [PL] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC). *Oncology Research and Treatment* 2016;39: Supplement 1
 - Smit E, Perol M, Reck M, Cappuzzo F, Bidoli P, Cohen R, et al. Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2015;33(15): Supplement 1.
 - Bidoli P, Cappuzzo F, Favaretto A, Alabiso O, Tiseo M, Chella A, et al. Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology. *Annals of Oncology*. 2015;26: Supplement 6
 - Garon E, Scagliotti G, Gautschi O, Reck M, Thomas M, Docampo L, et al. Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy. *European Journal of Cancer*. 2015;51: Supplement 3 (3073).
 - Ramalingam SS, Pérol M, Reck M, Kowalyszyn RD, Gautschi O, Kimmich M, et al. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial. *Clinical Lung Cancer*. 2018;19(3):270-9.e3.
 - Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D, et al. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. *Lung Cancer*.

2017;112:181-7.

- Garon E, Tsao A, Reck M, Levy B, Visseren-Grul C, Mao H, et al. P1.13-30 Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor and its Relationship to NSCLC Patient Outcomes in the REVEL Trial. Journal of Thoracic Oncology. 2018 Oct;13(10):S594.

Sbar 2010

- Sbar E, Besse B, Felip E, Shaw A, Ahn M, Salvati M, et al. A double-blind, randomized, parallel, two- arm phase II trial of BMS-690514 versus erlotinib in previous chemotherapy-treated non-small cell lung cancer (NSCLC) patients: A safety review. Journal of Thoracic Oncology. 2010;5(12): S538 - S9.

Scagliotti 2012

- Scagliotti G. A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy and Safety Study of Sunitinib (SU011248) In Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Erlotinib. Clinicaltrials.gov. July 2011: NCT00457392.
- EUDRA 2014 report: <https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001915-52/results>
- Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial. Journal of Clinical Oncology. 2012;30(17):2070 - 8.
- Thongprasert S, Tung Y, Kim JH, Chang GC, Park K, Su WC, et al. Sunitinib plus erlotinib for the treatment of advanced NSCLC: Subset analysis of east asian patients participating in a phase III trial. Journal of Thoracic Oncology. 2011;6(6): S551 - S2.
- Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, et al. Sunitinib (SU) in combination with erlotinib (E) for the treatment of advanced/metastatic nonsmall cell lung cancer (NSCLC): A phase III study. Annals of Oncology. 2010;21: viii3 - viii4.

Scagliotti 2014

- Scagliotti G. Randomized, Open Label, Phase 3 Trial of Erlotinib Alone Or In Combination With CP- 751,871 In Patients With Advanced Non6Small Cell Lung Cancer Of Non Adenocarcinoma Histology. Clinicaltrials.gov. April 2013: NCT00673049.
- Scagliotti GV, Bondarenko I, Blackhall F, Barlesi F, Hsia TC, Jassem J, et al. Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Annals of Oncology. 2014.

Schiller 2010

- Schiller JH. Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine. Clinicaltrials.gov. April 2018: NCT00111839.
- Schiller JH, Von Pawel J, Schutt P, Ansari RH, Thomas M, Saleh M, et al. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. Journal of Thoracic Oncology. 2010;5(12):1977 - 85.

SELECT 1, 2017

- Pasi J. Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1). Clinicaltrials.gov. May 2018: NCT01933932.
- Janne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crino L, et al. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. Jama. 2017;317(18):1844-53.
- Jänne PA, Van Den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, et al. Impact of PD-L1 status on clinical response in SELECT-1: Selumetinib + docetaxel in KRASm advanced NSCLC. Journal of Thoracic Oncology. 2017;12(1): S952-S3.
- Janne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crino L, et al. Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: results from the phase III SELECT-1 trial. Annals of Oncology. 2016;27(Supplement 6): vi552-vi87.

SIGN 2006

- Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIB or IV) non-small-cell lung cancer. Anti-Cancer Drugs. 2006;17(4):401 - 9.

Spigel 2011

- Spigel D. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or

Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer. Clinicaltrials.gov. August 2012: NCT00600015.

- Spigel DR, Burris HA, 3rd, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. *Journal of Clinical Oncology*. 2011;29(18):2582-9.
- Waterhouse D, Stults D, Daniel D, Griner P, Greco F, Burris H, et al. KRAS subset analysis from randomized phase II trials of erlotinib versus erlotinib plus sorafenib or pazopanib in refractory non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2013;31(15):8091.

Spigel 2012

- Spigel DR. Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients with Previously Treated Advanced Non-Small-Cell Lung Cancer. Clinicaltrials.gov. October 2015: NCT01027598.
- Spigel DR, Burris HA, Greco FA, Shih KC, Gian VG, Lipman AJ, et al. Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. *Cancer*. 2018 Jun 1;124(11):2355–64.
- Spigel D, Burris HA, Greco FA, Shih KC, Lipman AJ, Flora DB, et al. A randomized phase II study of pazopanib or placebo in combination with erlotinib in patients with advanced non-small-cell lung cancer. *Journal of Thoracic Oncology*. 2012;7(9): S208.

Spigel 2013

- Spigel D. A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Activity of MetMAB, a Monovalent Antagonist Antibody to the Receptor Met, Administered to Patients with Advanced Non-Small Cell Lung Cancer, in Combination with Tarceva (Erlotinib). Clinicaltrials.gov. September 2011: NCT00854308.
- Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt Jr JH, Blumenschein Jr GR, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. *Journal of clinical oncology*. 2013;31(32):4105 - 14.

Sun 2013

- Sun Y. Phase 3 Study of Pemetrexed versus Docetaxel in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy. Clinicaltrials.gov. December 2009: NCT00391274.
- Sun Y, Wu YL, Zhou CC, Zhang L, Liu XY, Yu SY, et al. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study. *Lung Cancer*. 2013;79(2):143 - 50.

TAILOR 2013

- Garassino MC, Martelli O, Broggin M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): A randomised controlled trial. *The Lancet Oncology*. 2013;14(10):981.
- Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, et al. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. *Ann Oncol*. 2015 Oct;26(10):2079-84.

TALISMAN 2015

- Gridelli C. A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (TALISMAN). Clinicaltrials.gov. October 2015: NCT01204697.
- Gridelli C, Chella A, Valmadre G, Allegrini G, Brighenti M, Bidoli P, et al. Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial. *Anticancer research*. 2016;36: 6535-40.

TAX 317 2000

- FDA report 2015: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020449s075lbl.pdf
- Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *Journal of Clinical Oncology*. 2000;18(10):2095 - 103.
- Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. *Lung Cancer*. 2004;43(2):183-94.

TITAN, 2012*

- Ciuleanu T. A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients with Advanced,

Recurrent, or Metastatic Non-Small Cell Lung Cancer(NSCLC). Clinicaltrials.gov. December 2014: NCT00556322.

- Ciuleanu T, Stelmakh L, Cicens S, Miliuskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. *The Lancet Oncology* 2012;13(3):300-08.
- Ciuleanu T, Stelmakh L, Cicens S, Gonzalez EE. Efficacy and safety of erlotinib versus chemotherapy in second-line advanced non-small-cell lung cancer (NSCLC) with poor prognosis: The phase III titan study. *Lung Cancer* 2011;71: S44.

TORI L-03 2013

- Garon EB, Dubinett SM, Kabbinar FF, Reckamp KL, Marquez-Garban DC, Goodglick L, et al. Randomized, multicenter phase II study of erlotinib (E) or E plus fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). *Journal of Clinical Oncology*. 2011;29(15).
- Garon EB, Siegfried JM, Dubinett SM, Elashoff RM, Park DJ, Parikh RJ, et al. Result of TORI L-03, a randomized, multicenter phase II clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). *Cancer Research*. 2013;73(8).

ULTIMATE IFCT-1103, 2016

- Cortot AB, Audigier-Valette C, Molinier O, Le Moulec S, Barlesi F, Zalcman G, et al. Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE. *Journal of Clinical Oncology*. 2016;34(Supplement): abstract 9005.
- Cortot AB, Audigier Valette C, Molinier O, Le Moulec S, Barlesi F, Zalcman G, et al. Prolonged OS of Patients Exposed to Weekly Paclitaxel and Bevacizumab: Impact of the Cross-Over in the IFCT-1103 ULTIMATE Study. *Journal of Thoracic Oncology* 2017;12(1): OA11.01.

V15-32 2008

- Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Phase III study, V- 15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. *Journal of Clinical Oncology*. 2008;26(26):4244 - 52.
- Sekine I, Ichinose Y, Nishiwaki Y, Yamamoto N, Tsuboi M, Nakagawa K, et al. Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: Results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. *Annals of Oncology*. 2009;20(9):1483 - 8.

Wen 2016

- Wen S, Fu X, Li G, He L, Zhao C, Hu X, et al. Efficacy of tamoxifen in combination with docetaxel in patients with advanced non-small-cell lung cancer pretreated with platinum-based chemotherapy. *Anticancer Drugs*. 2016 2016/06//;27(5):447-56.

Witta 2012

- Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, et al. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. *Journal of Clinical Oncology*. 2012;30(18):2248-55.

WJOG5108L 2014

- Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, et al. Randomized Phase III Study Comparing Gefitinib with Erlotinib in Patients with Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. *Journal of Clinical Oncology*. 2016; 34(27):3248-57.
- Katakami N, Morita S, Yoshioka H, Seto T, Urata Y, Satouchi M, et al. Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L. *Journal of Clinical Oncology*. 2014;32(15).
- Nishiyama A, Katakami N, Morita S, Seto T, Iwamoto Y, Hirashima T, et al. Randomized Phase III study comparing Gefitinib with Erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG5108L. *Annals of Oncology*. 2014;25(4): iv426–iv70.

ZEAL 2011

- De Boer R. A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients with Locally-Advanced or Metastatic NSCLC. Clinicaltrials.gov. April 2011: NCT00418886.
- De Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, et al. Vandetanib plus pemetrexed for the

second-line treatment of advanced non - small-cell lung cancer: A randomized, double-blind phase III trial. *Journal of Clinical Oncology*. 2011;29(8):1067 - 74.

- De Boer R, Arrieta O, Gottfried M, Blackhall FH, Raats J, Yang CH, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). *Journal of Clinical Oncology*. 2009;27(15):8010.

ZEST 2011

- Natale R. A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima™ Versus Tarceva® in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy. *Clinicaltrials.gov*. April 2011: NCT00364351.
- Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. *Journal of Clinical Oncology*. 2011;29(8): 1059-66.
- Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). *Journal of Clinical Oncology*. 2009;27(15):8009.

Zhang 2015

- Zhang Y, Gao C, Qu W, Gao Y, Zhu S, Zhang S, et al. A Randomized Phase II Study of Erlotinib Plus Nab-Paclitaxel Versus Erlotinib Alone as Second-Line Therapy for Chinese Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer. *Cancer Investigation*. 2015; Early Online:1– 5:1532-4192 online.

ZODIAC 2010

- Herbst R. A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination with ZD6474 (ZACTIMA™) Versus Docetaxel (TAXOTERE™) With Placebo in Subjects with Locally Advanced or Metastatic NSCLC. *Clinicaltrials.gov*. April 2011: NCT00312377.
- Herbst RS, Sun Y, Eberhardt WEE, Germonpre P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. *The Lancet Oncology*. 2010;11(7):619 - 26.
- Herbst RS, Sun Y, Korfee S, Germonpre P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). *Journal of Clinical Oncology*. 2009;27(18): CRA8003.
- Heymach J, Lockwood S, Herbst R, Johnson B, Ryan A. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. *Annals of Oncology*. 2014;25: 1941–8.
- Johnson B, Ryan A, J. H, Stephens C, Kennedy S, Langmuir P, et al. Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC. *Journal of Clinical Oncology*. 2010;28(15):7516.

*Trials in which patients in the control arm received chemotherapy (e.g., docetaxel or pemetrexed) at the investigators' discretion were included for the secondary analysis considering treatments categories

Update July 2018: New trials

East Asia S-1 Trial in Lung Cancer, 2017

- Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, et al. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). *Annals of Oncology*. 2017;28(11):2698-706.

Fandi, 2018

- Fandi Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer. *Clinicaltrials.gov*. July 2018: NCT02546986.

SELECT-2, 2017

- Jean-Charles Soria. Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment (SELECT-2). *Clinicaltrials.gov*. July 2018: NCT01750281.
- Soria JC, Fülöp A, Maciel C, Fischer JR, Girotto G, Lago S, et al. SELECT-2: a phase II, double-blind,

randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. *Annals of Oncology*. 2017;28(12):3028-36

Wu, 2017

- Wu Y, Feng J, Hu W, Luo Q. A randomized placebo-controlled clinical study of nab-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China. *Bioscience Reports*. 2017;37(4):BSR20170020.

Yu, 2018

- Yu Z, Lai J, He Z, Xu Z, Shi X, Zhang J, et al. Potential challenge for second-line treatments of unresectable locally or advanced-stage non-small-cell lung carcinoma unharbored sensitive driver gene mutation: a pilot study of novel antiangiogenesis inhibitor (NCT : 03256721). *ASCO* 2018. http://abstracts.asco.org/214/AbstView_214_225831.html

Update December 2018: New trials

ABOUND 2L 2018

- Morgensztern D, Cobo M, Ponce Aix S, Postmus PE, Lewanski CR, Bennouna J, et al. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). *Cancer*. 2018 Dec 15;124(24):4667–75.

JAVELIN 2018

- Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. *Lancet Oncol*. 2018 Nov;19(11):1468–79.

- Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, De Marinis F, et al. OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial. *Journal of Thoracic Oncology*. 2018 Oct;13(10):S331–2.